Anti-vegf therapy - Open Access .click

Results 231 to 240 of about 4,644,977 (251)

Predictive value of uninterrupted dry macula duration for discontinuation of anti-VEGF therapy in diabetic macular edema. [PDF]

Sci Rep
Murata T +4 more
europepmc +1 more source

Impact of anti-VEGF therapy on choroidal thickness in patients with retinal vein occlusion: a systematic review and meta-analysis. [PDF]

Front Med (Lausanne)
Cheng X, Zeng X, Liu S, Liu C, Liu Y, Xu G. +5 more
europepmc +1 more source

Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway [PDF]

International Journal of Molecular Sciences, 2018
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti ...
Yoshiro Itatani, Yoshiharu Sakai, Kenji Kawada +2 more
exaly +2 more sources

Some of the next articles are maybe not open access.

Related searches:

medicine
diabetic macular edema
anti-vegf

retinal vein occlusion
macular edema
vascular endothelial growth factor

retinopathy of prematurity
ophthalmology
anti-vascular endothelial growth factor

Incomplete Response to Anti-VEGF Therapy in Neovascular AMD: Exploring Disease Mechanisms and Therapeutic Opportunities

Progress in Retinal and Eye Research, 2021
Scott Cousins +2 more
exaly

Changes of Optical Coherence Tomography Biomarkers in Macular Edema Secondary to Retinal Vein Occlusion After Anti-VEGF and Anti-Inflammatory Therapies

Drug Design, Development and Therapy, 2022
Qiuming Li, Honghua Yu, Yijun Hu
exaly

Role of bFGF in Acquired Resistance Upon Anti-VEGF Therapy in Cancer

Cancers, 2021
Constantinos M Mikelis, Md S Sajib, Fatema Tuz Zahra +2 more
exaly

Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons

Clinical Ophthalmology, 2022
Frank Brodie, Dennis H Oh, Elana Meer
exaly